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Abstract
PURPOSE: To assess the effects of a soy dietary supplement on the main biomarkers of cardiovascular health in postmenopausal 
women compared with the effects of low-dose hormone therapy (HT) and placebo. METHODS: Double-blind, randomized 
and controlled intention-to-treat trial. Sixty healthy postmenopausal women, aged 40–60 years, 4.1 years mean time since 
menopause were recruited and randomly assigned to 3 groups: a soy dietary supplement group (isoflavone 90mg), a 
low-dose HT group (estradiol 1 mg plus noretisterone 0.5 mg) and a placebo group. Lipid profile, glucose level, body 
mass index, blood pressure and abdominal/hip ratio were evaluated in all the participants at baseline and after 16 
weeks. Statistical analyses were performed using the χ2 test, Fisher’s exact test, Kruskal-Wallis non-parametric test, analysis 
of variance (ANOVA), paired Student’s t-test and Wilcoxon test. RESULTS: After a 16-week intervention period, total 
cholesterol decreased 11.3% and LDL-cholesterol decreased 18.6% in the HT group, but both did not change in the soy 
dietary supplement and placebo groups. Values for triglycerides, HDL-cholesterol, glucose level, body mass index, blood 
pressure and abdominal/hip ratio did not change over time in any of the three groups. CONCLUSION: The use of dietary 
soy supplement did not show any significant favorable effect on cardiovascular health biomarkers compared with HT.
Clinical Trial Registry: The trial is registered at the Brazilian Clinical Trials Registry (Registro Brasileiro de Ensaios 
Clínicos – ReBEC), number RBR-76mm75.
Resumo
OBJETIVO: Avaliar os efeitos do uso de um suplemento alimentar à base de soja sobre os principais marcadores de 
risco cardiovascular e compará-los com o uso da terapia hormonal (TH) de baixa dose e grupo placebo em mulheres 
na pós-menopausa. MÉTODOS: Foram selecionadas 60 participantes do ambulatório de menopausa com idade entre 
40 e 60 anos, com idade média de 4,1 anos na menopausa para participar de um ensaio clínico randomizado, 
duplo-cego e controlado com duração de 16 semanas. As pacientes foram randomizadas em 3 grupos: um grupo 
que recebeu suplemento dietético à base de soja (isoflavona 90 mg), um grupo que recebeu TH em baixa dose 
(estradiol 1 mg e noretisterona 0,5 mg) e um grupo placebo. Os seguintes parâmetros foram avaliados no início e 
ao término das 16 semanas de intervenção: perfil lipídico, glicemia de jejum, índice de massa corpórea, pressão 
sanguínea arterial e circunferência abdominal. A análise estatística foi realizada usando-se o teste do χ2, teste exato 
de Fisher, teste não paramétrico de Kruskal-Wallis, análise de variância (ANOVA), teste t de Student pareado e teste de 
Wilcoxon. RESULTADOS: Ao final do período de intervenção de 16 semanas, houve uma diminuição do colesterol 
total em 11,3% e do LDL-colesterol em 18,6% no grupo da TH, porém ambos não tiveram mudanças tanto no grupo 
do suplemento alimentar à base de soja quanto no grupo placebo. Os valores de triglicérides, HDL-colesterol, glicemia 
de jejum, índice de massa corpórea, pressão sanguínea arterial e circunferência abdominal não mudaram ao longo 
da intervenção em nenhum dos grupos estudados. CONCLUSÃO: Do ponto de vista cardiovascular, o suplemento 
alimentar à base de soja não mostrou efeito favorável significativo nos marcadores de risco cardiovascular, quando 
comparado ao uso da TH.
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Introduction
Cardiovascular disease (CVD) remains the leading 
cause of mortality and morbidity in postmenopausal 
women1. Changes in lipids and lipoproteins at the time 
of menopause may contribute significantly to an increased 
risk for CVD development over a woman’s lifetime, mainly 
through a more atherogenic lipid profile2. 
It has been known for a long time that hormone 
therapy (HT) has favorable effect on lipid profile3,4. 
Following the Women’s Health Initiative study (WHI), 
there was a significant reduction in HT prescription for 
the treatment of menopause5. The search for comple-
mentary and alternative medicine (CAM) for the treat-
ment of menopausal women has increased significantly 
worldwide. Among CAM, there has been widespread 
the use of phytoestrogens in menopausal women6,7. 
In Brazil, a recent evaluation after the publication of 
the WHI study, which assessed the medical knowl-
edge of gynecologists with respect to the menopause 
and the treatment of symptomatic women, besides the 
repercussions of this knowledge on their attitudes and 
practice, reported that 46.3% of gynecologists had be-
gun to prescribe isoflavone and other natural therapies 
for menopausal symptoms8.
That is the reason for the intense research on the po-
tential benefits of soy protein and soy isoflavones on plasma 
lipids and lipoproteins as a way of reducing CVD risk. 
Consumption of products containing soy is widely 
variable in the world and there is no accurate statistics 
about the amount of soy ingested and the type and quality 
of soy protein ingested. The Study of Women’s Health 
Across the Nation (SWAN), a multisite, longitudinal 
US cohort study, found substantial variation in dietary 
isoflavone intake by race/ethnicity among 3,133 women 
who were premenopausal or early perimenopausal at 
baseline. Approximately 40% of non-Asian US women 
in SWAN consumed no daidzein or genistein, the most 
prevalent isoflavones6.
Soy is a rich source of the genistein, daidzein and 
glycitein isoflavones. Isoflavones are structurally similar 
to estradiol and have a higher binding affinity for the 
beta-estrogen receptor, the primary estrogen receptor in 
the vascular wall, than for the alpha-estrogen receptor4,9. 
Although there have been mixed results, some clinical 
trials have demonstrated a beneficial effect of dietary soy 
protein on plasma lipids and lipoproteins10,11. A number 
of studies have shown that isoflavones might neutralize 
or slow down the rate of LDL-cholesterol oxidation, as 
a result of this antioxidant effect4,9,12. In contrast, there 
are several studies showing a non-significant effect on the 
reduction of oxidative damage or no favorable alteration 
in blood lipids13-15. 
Although soybean has been considered food with 
functional properties, that is capable of reducing cho-
lesterol according to the Food and Drug Administration 
(FDA)16, which recommends the intake of 25 g/day of 
soy protein as part of a low-fat and cholesterol diet in 
order to reduce the risk of cardiovascular diseases, some 
reports have indicated that a large amount of industrial-
ized soy-derived products contain varying quantities of 
isoflavones. Therefore, the purpose of this study was to 
evaluate the effects of isolated soy protein-containing 
isoflavones 90 mg on several biomarkers of cardiovascular 
health in menopause, mainly serum lipoproteins, which 
are normally used as indexes for cardiovascular disease, 
and to compare the results with the effects of low-dose 
hormone therapy and placebo.
Methods
Study participants
Sixty participants were recruited from two Menopause 
Outpatient Clinics of the Women’s Integrated Healthcare 
Center at the University of Campinas (UNICAMP) 
in Campinas (SP), and Leonor Mendes de Barros Maternity 
Hospital in São Paulo (SP), Brazil, to participate in a 
16-week double-blind, randomized placebo-controlled 
trial designed to examine the effect of soy dietary 
isoflavone supplementation on clinical biomarkers of 
cardiovascular health and serum changes in lipid profile 
and fasting glucose. The study design and participant 
enrollment have been reported in detail previously17.
Sample size was based on standard power simulation, 
admitting a 5% threshold for alpha (type I error prob-
ability) and adopting a power of 80%. Based on previous 
studies, subjects selected for the isoflavone treatment had 
a mean difference in HDL-cholesterol baseline value and 
after treatment of 4.1 and a standard deviation of 6.718. 
The sample size for establishing this difference was 23 
subjects. Therefore, with a pool of 20 patients and an alpha 
error of 5%, we had approximately 74% power to detect a 
difference. Estimates from this statistical analysis suggest 
that our study had sufficient statistical power to detect 
real effects, so our findings can be considered reliable. 
Inclusion criteria were postmenopausal women 
between 40 and 60 years of age, who had had their last 
menstrual period longer than 12 months before the 
study and a follicle-stimulating hormone greater than 
30 mUI/mL, estradiol levels lower than 20 pg/mL, those 
who had not been on any type of hormonal treatment 
during the previous six months and were not currently 
using lipid lowering drugs, antidiabetic medication, 
soybean derived products, or herbal supplements. 
Exclusion criteria were history of hysterectomy, chronic 
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gastrointestinal disorder, any contra-indication for HT 
or for participation in a conflicting clinical trial. Finally, 
women were excluded if they had a known allergy or 
hypersensitivity to soy or cow milk or were not willing 
to avoid soy products for the 16-week study period. 
The Research Ethics Committee approved the protocol, 
and all participants provided a signed Informed Consent 
Form. The trial is registered at the Brazilian Clinical 
Trials Registry (Registro Brasileiro de Ensaios Clínicos 
– ReBEC), number RBR-76mm7519. ReBEC is an open 
access virtual platform for registration of ongoing or 
concluded experimental and non-experimental studies on 
humans, performed in Brazil and elsewhere. ReBEC is a 
joint project of Brazilian Ministry of Health, The Pan-
American Health Organization (PAHO) and The Oswaldo 
Cruz Foundation (FIOCRUZ). The studies data registered 
on ReBEC comply with the dataset requirements of the 
International Committee of Medical Journal Editors 
(ICMJE) and the World Health Organization (WHO)19. 
Randomization and intervention 
After initial screening, 60 women were assigned 
to 3 different treatments in a sequence determined by 
a computerized random-number generator. All patients 
received a numerical randomized envelope, with a letter 
inside labeled #1, #2 or #3, corresponding to HT, isofla-
vone 90 mg per day and placebo, respectively. During the 
study, the subjects and study personnel were not informed 
about the order of treatment. Study drugs were packaged 
in 30-day flasks. Follow-up visits were conducted by a 
gynecologist who did not participate in the screening 
part of this study or in drug distribution. The women 
were randomly assigned to one of three treatment groups, 
with daily oral intakes as follows: HT (n=20): 1 tablet of 
estradiol 1 mg + noretisterone acetate 0.5 mg (Activelle®, 
Medley Pharmaceuticals, Campinas, SP, Brazil) associated 
with 2 portions/day of placebo powder; isoflavone group 
(n=20): 2 portions/day of a food powder with isoflavone 
45 mg/portion, totalizing 90 mg of isoflavone/day (Previna®, 
Sanavita Functional Foods, Piracicaba, SP, Brazil) and 1 
placebo tablet; placebo group (n=20): 1 placebo tablet 
and 2 portions/day of placebo powder.
The isoflavone intervention consisted of 20 g/por-
tion of a food powder containing 12 g of soy protein and 
45 mg of total isoflavones (26.5 mg aglycones) to be 
mixed with 200 mL of any beverage. The soy intervention 
contained approximately 8 mg of total daidzein, 15 mg 
of total genistein and 3.5 mg of total glycitein. 
The dietary soy supplement (Previna®, Sanavita 
Functional Foods, Piracicaba, SP, Brazil) consisted of 20 g 
portions of a food powder containing 12 g of soy protein 
and a total of 45 mg of isoflavones (26.5 mg of aglycons) 
to be mixed with 200 mL of water. The soy supplement 
contained approximately 8 mg of total daidzein, 15 mg 
of total genistein and 3.5 mg of total glycitein. The pla-
cebo powder (Sanavita Functional Foods) contained 20 g 
of maltodextrin, was identical in appearance to the soy 
powder and contained the same nutrients and calories ex-
cept for the isoflavones and soy protein. Both supplements 
also contained 488 mg of calcium carbonate and 1.2 mg 
of hydrolyzed collagen per portion. The supplement was 
taken twice a day for a total of 16 weeks. 
The placebo tablet was taken once a day. It was iden-
tical in appearance to the HT tablet and was produced 
by Medley Pharmaceuticals. 
Measurements 
At the screening visit, women answered a standard-
ized questionnaire, which ascertained information about 
demographic characteristics including age, ethnicity, 
educational level and social status. Women were also 
queried about reproductive history, age at menopause, 
time since menopause, use of medication, history of 
cigarette smoking and frequency of alcohol use. Height 
was measured to the nearest 0.5 cm and weight to the 
nearest 0.1 kg, in light clothing and without shoes. 
Body mass index (BMI) was calculated as weight (in 
kg)/height (in m2). Blood pressure was measured with 
a mercury sphygmomanometer after the participant had 
been seated quietly for at least five minutes. The waist/
hip ratio was calculated using the minimum perimeter 
between the lowest rib and the anterior superior iliac 
crest as the waist measure, and the maximum perimeter 
at the gluteus as the hip measure20.
Data were collected in the three groups at baseline 
and at 16 weeks of study. Blood was drawn for total lipid 
levels, lipoprotein levels and glucose analysis after the 
women had fasted for 12 hours overnight. Plasma glucose 
was measured by a glucose oxidase assay. Plasma total 
cholesterol and triglyceride levels were measured using 
enzymatic techniques, and lipoproteins were determined 
according to the National Institute of Health lipid 
research clinics method (commercial kits by Roche®). 
Inter-run coefficients of variation were 1.5% (TG), 0.8% 
(TC) and 1.3% (HDL-c). LDL cholesterol was calcu-
lated using the Friedwald equation: LDL-cholesterol = 
total cholesterol – HDL-cholesterol – (triglycerides/5). 
The Castelli I index was calculated as the ratio between 
total cholesterol and HDL-cholesterol, and the Castelli 
II index as the ratio between LDL-cholesterol and 
HDL-cholesterol21.
Compliance was assessed by patient self-report of the 
number of packets of product missed, which was then 
converted to the percentage of prescribed packets ingested. 
Compliance was high (99.5%) and no dropouts occurred 
in any of the three groups during the study period.  
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Statistical analysis
Data were analyzed according to the intention-to-
treat principle, including all original participants in the 
group to which they were randomly assigned. Data of 
epidemiologic and clinical characteristics were analyzed 
including the χ2 test, Fisher’s exact test, the Kruskal-
Wallis non-parametric test and analysis of variance 
(ANOVA). Results shown as the means with observa-
tions at baseline and after treatment were compared 
in the same group, using a paired Student’s t-test and 
Wilcoxon test. Intra-group and inter-group differences 
were evaluated using repeated-measures analysis of co-
variance, followed by the Tukey test, and non-parametric 
Kruskal-Wallis test, followed by the Mann-Whitney 
test22. Results were considered statistically significant 
when alpha error (p-values) was less than 0.05. SAS 
software, version 9.1.3 (SAS Institute Inc., Carey, NC, 
USA), was used to perform the analyses23.
Results
A total of 1,520 patients were screened in both study 
centers in order to select 60 participants. The study was 
conducted in a tertiary reference center and the subjects were 
patients who presented with a high incidence of associated 
disorders, in addition to the climacteric syndrome. This fact 
made patient inclusion difficult and prolonged the neces-
sary period to achieve 60 eligible subjects. Women assisted 
at menopause outpatient clinics were invited to answer 
a checklist in order to meet study criteria. The majority 
of screened women (95%) were excluded from the study 
after failing to meet inclusion criteria and because some of 
them had no interest in participating in the study (5%). 
Most (n=1,370) were excluded in the first pre-randomization 
visit and the main reasons were: 54% – hypertension; 
40% – obesity; 28% – hysterectomy; 22% – metabolic 
syndrome; 8% – diabetes mellitus. In addition, 30% had 
some type of gynecological cancer and 40% were on HT 
or non-hormone therapy for climacteric syndrome (more 
than one condition per patient). At the second pre-random-
ization visit, 90 women were considered ineligible due to: 
screening altered for endometrial thickness, some altered 
findings on mammography, estradiol level higher than 20 
pg/mL and lipid profile and/or fasting glucose with high 
levels, requiring immediate treatment with specific drugs. 
At the randomization visit, the remaining 60 women were 
equally randomized into 3 groups, as shown in Figure 1. 
These groups were observed for 16 weeks and there were 
no dropouts and no one was lost to follow-up. 
Table 1 shows the baseline characteristics of the 
participants by intervention group. There were no sig-
nificant differences between the groups. The average age 
was 52.4 (±3.9) years. Women were on average 4.1 (±3.3) 
years post-menopause and the mean age at menopause 
was 48 (±3.7) years. The average educational level was 
6.8 (±4.1) years. 
Cardiovascular risk parameters such as waist cir-
cumference, circumference of the hip, waist/hip ratio, 
and systolic and diastolic blood pressure did not change 
over the treatment period among the three groups. There 
Women screened
n=1,520
Pretreatment visit
n=150
Randomization week
n=60
Excluded
n=1,370
Reasons:
Ineligible – 1,301
Not interested – 69
Reason:
Abnormal screening 
tests – 90
Intention to treat=60
No dropouts or exclusions
Excluded
n=90
HT
n=20
Soy
n=20
Placebo
n=20
Figure 1. Flow chart of the study participants
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was an increase in weight and BMI only in the placebo 
group, which showed an average increase of 1.3 kg over 
the 16-week study period. When we compared treatment 
effect among the groups, no statistically significant dif-
ferences were observed.
At the end of the 16-week treatment, total cholesterol 
plasma levels showed 11.3% decrease in the HT group, 
but the isoflavone and placebo groups showed no changes. 
LDL serum levels decreased by 18.6% in the group that 
received HT and there was no change in the other groups. 
Plasma triglyceride, HDL and glucose levels did not 
change in any of the groups. The Castelli I and II indices 
showed a positive relationship only in the group that used 
HT, with a reduction of 15.9 and 21.7%, respectively. 
When we compared treatment effect among the groups, 
a significant improvement in total cholesterol and LDL-
cholesterol in the HT group was observed, compared 
with the soy and placebo groups (Table 2).
There were no statistically significant differences 
in the adverse effects evaluated (mastalgia, vaginal 
bleeding, allergy, headache, nausea, weight gain, water 
retention and intestinal complaints) between the three 
treatment groups. The adverse effects have been reported 
in detail previously17.
Discussion
The results showed that dietary soy supplement had 
no significantly favorable effect on cardiovascular health 
biomarkers, when compared to HT use. Of all the clinical 
markers evaluated, only weight and BMI were slighted 
increased in the placebo group (1.3 kg). The results have 
indicated that hormonal changes, in particular, estrogen 
deficiency that take place in the menopausal transition 
cause an increase in weight and BMI. Studies have shown 
that naturally menopausal women have significantly higher 
BMIs than women treated with HT in the menopausal 
period24. HT protects women against an increase in BMI. 
This could explain why women receiving a placebo had 
increased BMI in this study. In contrast, HT use did not 
change BMI nor did isoflavone use. Maesta et al.25 found 
no increase in BMI, waist circumference and body fat in 
women receiving 25 g of soy protein. 
The results of this trial do not support the hypothesis 
that isoflavones from soy protein have beneficial effects on 
plasma lipids in post-menopausal women. In this study, 
there was an increase in HDL-cholesterol (10.2%) and 
a slight decrease in LDL (-1.9%) and total cholesterol 
(-0.7%) in soy groups, but these differences compared 
to baseline values were not statistically significant. 
These results are similar to previous studies aimed at 
menopausal women who received soy dietary supplement, 
which did not demonstrate any favorable effect on lipid 
Characteristics
Groups
HT Soy Placebo p-value
Mean age (years±SD) 53.3±4.5 52.9±3.5 50.9±3.4 0.1*
Age at menopause (years)
Median (Q1–Q3)
48.0 
(47.0–50.5)
49.0
(47.5–50.5)
48.0
(46.0–50.0)
0.4**
Time since menopause (years)
Median (Q1–Q3)
5.6
(1.5–10)
2.5
(1.5–4.0)
2.5
(1.0–5.5)
0.1**
Education 
(years of schooling±SD) 6.6±4.2 7.6±4.4 6.3±3.9 0.7*
Skin color (%)
White
Non-white
65.0
35.0
40.0
60.0
70.0
30.0
0.1***
Parity (%)
≤2
>2
45.0
55.0
65.0
35.0
40.0
60.0
0.3****
Social status (%)
A/B classes
C/D/E classes
40.0
60.0
55.0
45.0
45.0
55.0
0.6***
Smoking habits (%)
Current smoker/ex-smoker
Never smoked
60.0
40.0
35.0
65.0
45.0
55.0
0.6***
Body mass index (kg/m²)
Median (Q1–Q3)
25.9
(24.0–28.5) 
26.4
(24.2–28.8) 
26.6
(24.1–30.0)
0.3**
Table 1. Characteristics of the women according to study group (n=60)
*ANOVA test; **Kruskal-Wallis non-parametric test; ***χ2 test; ****Fisher’s exact test.
HT: hormone therapy; SD: standard deviation; Q1: first quartile; Q3: third quartile.
Variables HT (n=20) Soy (n=20) Placebo (n=20) p-value
Total cholesterol* -11.3 (-15.3 – -7.4) -0.7 (-5.3 – 4.0) 4.6 (-2 – 11.2) <0.01
HDL-cholesterol** 8.3 (-0.1 – 16.7) 10.2 (-1.9 – 22.2) 6.1 (-1.5 – 13.6) 0.9
LDL-cholesterol* -18.6 (-26.0 – -11.2) -1.9 (-8.6 – 4.8) 5.5 (-4.9 – 15.9) <0.01
Triglycerides* -0.1 (-17.6 – 17.4) -1.1 (-13.7 – 11.5) 21.3 (-15.6 – 58.1) 0.3
Glucose* -0.8 (-5.1 – 3.5) 3.1 (-0.3 – 6.5) 0,5 (-4.5 – 5.5) 0.4
Castelli index I** -15.9 (-23.6 – -8.2) -5.9 (-15.5 – 3.7) 0.8 (-8.5 – 10.2) 0.02
Castelli index II** -21.7 (-33.5 – -9.8) -6.1 (-18.4 – 6.1) 1.8 (-10.5 – 14.1) 0.01
Table 2. Mean percentage variation (confidence interval of 95%) of lipid profile and glucose at baseline and follow-up per treatment group
*Co-variance ANOVA test (followed by Tukey test); **non-parametric Kruskal-Wallis test (followed by Mann-Whitney test). 
p-value for difference between groups: Total cholesterol – HT versus soy<0.01; HT versus placebo<0.01; soy versus placebo=0.3; LDL-cholesterol – HT versus soy=0.01; 
HT versus placebo<0.01; soy versus placebo=0.4; Castelli Index I – HT versus soy=0.2; HT versus placebo=0.01; soy versus placebo=0.5; Castelli Index II – HT versus soy=0.1; 
HT versus placebo=0.01; soy versus placebo=0.6.
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profile13,15,26,27. In a recent review, the North American 
Menopause Society Isoflavone Report (2011) concluded 
that any cardiovascular benefit derived from soy protein 
or isoflavone supplements would be minimal and there 
is a need for greater standardization and documentation 
of clinical trial data on soy28.
On the other hand, some significant trials have 
reported a generally consistent finding in support of the 
beneficial role of soy foods or protein in lipid profiles. 
Anderson et al.10 published a meta-analysis including 
38 trials, observing a decrease in serum lipids: total 
cholesterol (9.3%), LDL-cholesterol (12.9%) and tri-
glycerides (10.5%), and an increase in HDL-cholesterol 
(2.4%). A meta-analysis by Zhan and Ho11 of 23 ran-
domized clinical trials conducted from 1995 to 2002 
demonstrated that the intake of soy protein containing 
isoflavones was associated with a better lipid profile: 
a 3.77% decrease in serum total cholesterol, 5.25% 
in LDL-cholesterol and 7.27% in triglycerides, and a 
significant 3.03% increase in serum HDL-cholesterol. 
A double-blind placebo controlled trial published by 
Nahas et al.29, with 50 menopausal women using 60 mg 
of isoflavones in tablets in a period of 6 months, showed 
a decrease in LDL-cholesterol (11.8%) and an increase 
in HDL-cholesterol (27.3%) in soy group compared to 
placebo group. A review conducted by Dewell et al.30 
concluded that both soy protein and soy isoflavone ex-
tracts resulted in reductions in total plasma cholesterol 
concentrations, but the authors conclude that these 
decreases were likely too small to be clinically beneficial 
in the reduction of CVD. 
Research studies have suggested that the beneficial 
effects of soy might be due to isoflavone activity by three 
major mechanisms: 1) directly through estrogen receptor 
(ER) mediated effects; 2) directly through ER-independent 
effects on cardiovascular risk factors and putative athero-
genic risk factors and 3) indirectly by displacement of 
animal protein intake28. However, not all studies have 
reported a cholesterol-lowering effect of isoflavones7,15. 
Some investigators have used a variety of protocols, in-
cluding a range of isolated soy proteins, varying doses of 
isoflavones, different trial lengths, and diverse population 
subgroups in an attempt to delineate the components of 
soy protein matrix, doses, and circumstances whereby soy 
could be effective in improving human lipid profiles11,28. 
Possible explanations for our findings may be gender-
related, since the most significant reductions in total 
cholesterol and LDL-cholesterol levels were observed in 
men rather than in women, in premenopausal rather than 
in post-menopausal women and in hyperlipidemic women 
rather than in normal lipidemic women11. However, 
when comparing isoflavone with low-dose HT, this last 
intervention was also able to reduce the lipid profile in 
normal lipidemic post-menopausal women in a period of 
16 weeks. Furthermore, the conflicting results obtained 
from studies on isoflavones may also have been due to 
differences in supplement form, intake amount, genetic 
factors and individual absorption ability (equol producers 
versus equol non-producers)28.
It has been suggested that equol production could 
be induced with probiotics, the most commonly used 
being Lactobacilli and Bifidobacteria. Whether an equal-
producing capacity is a determinant of the cardiovascular 
benefit of soy is uncertain until now31. 
Some critics may question that the length of soy 
isoflavone use is too short to elicit a satisfactory clinical 
response. However, other authors observed that the most 
significant lowering effect of isoflavone soy protein contents 
on lipid profile occurred within the initial short period of 
isoflavone exposure, and the extent of the lipid lowering 
effect decreased as the duration of intervention increased. 
This fact can be attributed to a physiologic adaptation 
mechanism to a more prolonged supplementation, by not 
paying attention to diet or lower adherence in prolonged 
periods of intervention11,32. Therefore, the length of use 
was satisfactory to induce effects on lipid profiles.
Investigation of fasting glucose in this trial had no 
significant change in any group. Menopausal transition is 
accompanied by a decrease in insulin secretion and hepatic 
insulin clearance33. Review studies have reported the ben-
eficial effects of estrogen therapy on glucose homeostasis34 
and some data suggest that postmenopausal women with 
type 2 diabetes mellitus who use oral estrogen therapy may 
require lower doses of medications for glycemic control3. 
Soy isoflavones, with structural similarity to estrogens, 
may also exert their biological effects through estrogen-
mediated mechanisms and might be beneficial for glucose 
homeostasis and alleviation of diabetes35. In a recent trial 
published by Ho et al.15, moderate but significant differ-
ences were observed in changes and percentage of changes 
in fasting glucose among the studied groups, but the 
effects were much more apparent in women with high 
baseline fasting glucose concentration (>100 mg/dL) than 
in those with lower baseline values (<90 mg/dL). In our 
trial, the mean fasting glucose was lower than 100 mg/
dL and this may be a possible cause for no significant 
change in fasting glucose level in our intervention. The 
real influence of soy isoflavones on serum glucose levels 
remains uncertain.
International societies are cautious about recom-
mending foods or supplements containing isoflavones. 
Some professionals or even the media have recommended 
isoflavones, especially for the cardiovascular benefits 
of these foods, but the observed health effects cannot 
be clearly attributed to isoflavones alone. Soy and soy 
isoflavones had such a small effect on plasma lipid 
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profiles that they probably did not reduce the risk of 
cardiovascular disease28,36,37. 
This trial is one of the few studies that have compared 
three intention-to-treat interventions, measuring the effect 
of low-dose HT, a dietary soy supplement and placebo in 
the same study, with the purpose of determining the effects 
of soy isoflavones on several biomarkers of cardiovascular 
health, mainly serum lipoproteins, which are normally 
used as indexes for cardiovascular disease and comparing 
the results with the effects of HT and placebo. Thus, this 
study may contribute to guide the intake of dietary soy 
supplement, providing a scientific basis and avoiding the 
indiscriminate use of any food containing isoflavone. 
This 16-week randomized controlled double-blind 
intention-to-treat trial indicates that consumption of a soy 
dietary supplement containing 90 mg of isoflavones was 
not associated with a significant effect on cardiovascular 
health biomarkers. The studied population was com-
posed of postmenopausal women with previous normal 
lipid profile and probably that is one of the reasons for 
our findings. On the other hand, low-dose HT showed 
a significantly beneficial effect on lipid profile. Future 
studies with long-term interventions involving different 
baseline subject characteristics and the inclusion of clini-
cal endpoints would be useful and desirable. 
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